---
title: "Definium Therapeutics (DFTX) Gets a Buy from Jefferies"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295271269.md"
description: "Jefferies analyst Andrew Tsai maintained a Buy rating on Definium Therapeutics (DFTX) with a $65 price target. Additionally, Canaccord Genuity reiterated a Buy rating with a $58 target. Tsai is noted as a 5-star analyst covering the Healthcare sector."
datetime: "2026-08-07T19:16:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295271269.md)
  - [en](https://longbridge.com/en/news/295271269.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295271269.md)
---

# Definium Therapeutics (DFTX) Gets a Buy from Jefferies

Jefferies analyst Andrew Tsai maintained a Buy rating on Definium Therapeutics today and set a price target of $65.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Tsai is a 5-star analyst with an average return of 32.2% and a 63.64% success rate. Tsai covers the Healthcare sector, focusing on stocks such as Biogen, Definium Therapeutics, and Moderna.

In a report released today, Canaccord Genuity also reiterated a Buy rating on the stock with a $58.00 price target.

### Related Stocks

- [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)
- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)

## Related News & Research

- [Definium Therapeutics (DFTX) Receives a Buy from Wells Fargo](https://longbridge.com/en/news/295787298.md)
- [What Do Definium Therapeutics (DFTX) Phase 3 GAD Results Mean For DT120?](https://longbridge.com/en/news/295821556.md)
- [This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday](https://longbridge.com/en/news/296231890.md)
- [Definium Therapeutics Says Unprecedented Efficacy From Anxiety Study 'Raises the Bar'](https://longbridge.com/en/news/295680444.md)
- [Septerna, Inc. (SEPN) Receives a Rating Update from a Top Analyst](https://longbridge.com/en/news/296029142.md)